Pembrolizumab/Berahyaluronidase alfa

帕博利珠单抗/比拉透明质酸酶α

Report date: 2026/05/16 20:00:17

Base Information

Drug NamePembrolizumab/Berahyaluronidase alfa
Drug Alias NameMK-3475/MK-5180MK-3475/VX-869Pembrolizumab/MK-5180Pembrolizumab/VX-869Recombinant human hyaluronidase and pembrolizumab (Merck) +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionProgrammed cell death protein 1 blockersHyaluronic acid modulators
TargetsProgrammed cell death protein 1Hyaluronic acid
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaSolid tumoursMicrosatellite instability-high cancer +[25] 
Global Approved IndicationsSolid tumoursMicrosatellite instability-high cancerMismatch Repair Deficient Cancer +[20] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/09/19
Country/TerritoryCanadaUnited StatesUkraine +[27] 
CombinationsYes Pembrolizumab
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme BvBaxter Oncology GmbhMerck & Co Inc +[5] 
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaSolid tumoursMicrosatellite instability-high cancer +[25] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A